Drug-eluting stents: current issues
Early stent thrombosis occurs in about 1% to 1.5% of patients with drug-eluting stents, very similar to the rate with bare-metal stents. Late stent thrombosis is more of a concern with drug-eluting stents, with an incidence of at least 0.35%. I would urge caution if you feel you have to stop antiplatelet therapy in patients with drug-eluting stents. While neointima formation peaks at 6 months and then may actually regress with bare-metal stents, it continues to grow with drug-eluting stents--although this process appears to plateau by 4 years with sirolimus. With the others, we have to wait and see. We still don't know the best drug-eluting stent. Trials are under way to compare stents with surgery, and the future brings the arrival of a number of exciting new devices and approaches that are now entering clinical trials.
|Keywords||*Blood Vessel Prosthesis, *Coated Materials, Biocompatible, *Stents, Blood Vessel Prosthesis Implantation/*instrumentation, Coronary Vessels/*surgery, Graft Occlusion, Vascular/epidemiology/prevention & control, Humans, Incidence, Myocardial Ischemia/*surgery|
Serruys, P.W.J.C., & Ong, A.T.L.. (2005). Drug-eluting stents: current issues. Texas Heart Institute Journal. Retrieved from http://hdl.handle.net/1765/10402